C4 Therapeutics Q2 EPS Lifted by Brookline Capital Markets

C4 Therapeutics, Inc. (NASDAQ:CCCC) – Stock analysts at Brookline Capital Markets raised their Q2 2026 earnings per share (EPS) estimates for shares of C4 Therapeutics in a note issued to investors on Tuesday, May 12th. Brookline Capital Markets analyst L. Cann now forecasts that the company will post earnings per share of ($0.20) for the quarter, up from their prior forecast of ($0.21). The consensus estimate for C4 Therapeutics’ current full-year earnings is ($1.01) per share. Brookline Capital Markets also issued estimates for C4 Therapeutics’ Q3 2026 earnings at ($0.21) EPS, Q4 2026 earnings at ($0.22) EPS, FY2026 earnings at ($0.83) EPS, FY2027 earnings at ($0.98) EPS, FY2028 earnings at ($1.71) EPS, FY2029 earnings at $6.14 EPS and FY2030 earnings at $23.44 EPS.

Several other research firms have also weighed in on CCCC. boosted their target price on shares of C4 Therapeutics from $20.00 to $30.00 and gave the company a “buy” rating in a research note on Monday, February 23rd. TD Cowen restated a “buy” rating on shares of C4 Therapeutics in a research report on Thursday, February 26th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of C4 Therapeutics in a research report on Monday, April 20th. Barclays increased their price objective on shares of C4 Therapeutics from $5.00 to $7.00 and gave the stock an “overweight” rating in a research note on Thursday, February 26th. Finally, Wall Street Zen raised shares of C4 Therapeutics from a “strong sell” rating to a “hold” rating in a report on Saturday, February 28th. Five research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $7.75.

C4 Therapeutics Price Performance

Shares of CCCC opened at $3.63 on Friday. The stock has a market capitalization of $399.96 million, a PE ratio of -3.05 and a beta of 2.77. The business’s fifty day moving average price is $2.87 and its 200 day moving average price is $2.48. C4 Therapeutics has a 12-month low of $1.21 and a 12-month high of $3.95.

C4 Therapeutics (NASDAQ:CCCC) last issued its quarterly earnings results on Tuesday, May 12th. The company reported ($0.20) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.25) by $0.05. The business had revenue of $6.15 million during the quarter, compared to the consensus estimate of $4.42 million. C4 Therapeutics had a negative return on equity of 50.68% and a negative net margin of 297.76%.

Hedge Funds Weigh In On C4 Therapeutics

Several hedge funds and other institutional investors have recently modified their holdings of the company. Zacks Investment Management bought a new position in shares of C4 Therapeutics during the third quarter worth about $29,000. Caitong International Asset Management Co. Ltd acquired a new position in C4 Therapeutics during the 3rd quarter valued at about $43,000. Delta Investment Management LLC acquired a new position in C4 Therapeutics during the 4th quarter valued at about $38,000. Virtu Financial LLC bought a new position in C4 Therapeutics in the 4th quarter worth about $39,000. Finally, Engineers Gate Manager LP grew its position in C4 Therapeutics by 49.9% in the 4th quarter. Engineers Gate Manager LP now owns 24,416 shares of the company’s stock worth $47,000 after purchasing an additional 8,130 shares during the last quarter. Institutional investors and hedge funds own 78.81% of the company’s stock.

About C4 Therapeutics

C4 Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted protein degraders. Utilizing its proprietary Controlled Inducible Degradation (CiD) platform, the company seeks to eliminate disease-causing proteins by harnessing the body’s natural protein disposal machinery. This approach aims to address a wide range of oncology and immuno-oncology indications by targeting proteins that have historically been difficult to inhibit with traditional small molecules or antibodies.

The company’s pipeline includes multiple small-molecule degrader candidates advancing through preclinical and clinical stages.